A Study With Imlifidase in Anti-GBM Disease

Summary

An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

Timeline

Start

2022-12-22

Primary completion

2025-06-23

Completion

2026-02-02

Outcome

Missed primary endpoint

Stopped: “Company decision, not due to any safety reason.”

release “GOOD-IDES-02 said ”Although the trial did not meet the primary endpoint” hansabiopharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imlifidase	Protein / enzyme biologic	0.5 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	—

Indications